Skip to main content

Market Overview

Horizon Therapeutics: Q3 Earnings Insights



Shares of Horizon Therapeutics (NASDAQ:HZNP) decreased 2.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 171.88% over the past year to $1.74, which beat the estimate of $0.94.

Revenue of $636,427,000 up by 89.71% year over year, which beat the estimate of $517,680,000.


The upcoming fiscal year's revenue expected to be between $2,120,000,000 and $2,140,000,000.

Details Of The Call

Date: Nov 02, 2020

Time: 08:00 AM

ET Webcast URL:

Price Action

52-week high: $86.67

Company's 52-week low was at $23.81

Price action over last quarter: Up 1.08%

Company Profile

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.


Related Articles (HZNP)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at